At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 8,000 target
Drug / intervention
Radiation therapyradiation
Likely dose
Not stated in record
Key inclusion· 3
- ✓Undergoing or has completed imaging or treatment procedures on an MR-Linac
- ✓Written informed consent provided
- ✓Age 18 years or older
Key exclusion· 1
- ✕MRI contraindications including pregnancy, claustrophobia, or incompatible metal/electronic implants
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
In Brief
An observational study evaluating Radiation therapy for Oncology and 37 related conditions. Currently recruiting, targeting 8,000 participants across 18 sites in 9 countries.
Signals
Enrolling ahead of pace
Detailed Summary
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer, Brain Tumor, Brain Cancer, Gynecologic Tumor, Prostate Tumor, Prostate Neoplasm, Breast Tumor, Radiation Toxicity, Quality of Life, Rectal Cancer, Rectal Tumor, Rectal Neoplasms, Lung Cancer, Lung Tumor, Lung Neoplasm, Esophageal Cancer, Esophagus Cancer, Esophageal Tumor, Esophageal Neoplasm, Esophagus Tumor, Esophagus Neoplasm, Pancreatic Cancer, Pancreatic Tumor, Pancreatic Neoplasms, Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Tumor, Tumor, Neoplasms, Bladder Cancer, Bladder Neoplasm, Liver Cancer, Liver Neoplasms, Liver Metastases, Oligometastases
CountriesAustralia, Belgium, Canada, Denmark, Germany, Italy, Netherlands, United Kingdom, United States
CollaboratorsThe Netherlands Cancer Institute, Sunnybrook Health Sciences Centre, M.D. Anderson Cancer Center, The Christie NHS Foundation Trust, Royal Marsden NHS Foundation Trust, Medical College of Wisconsin, Elekta Limited, Odense University Hospital, Radboud University Medical Center, Radiotherapiegroep, Jules Bordet Institute, University Hospital Tuebingen, Radiotherapeutic Institute Friesland, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), IRCCS Sacro Cuore Don Calabria di Negrar, Austin Health, Princess Margaret Hospital, Canada, Università degli Studi di Brescia
Timeline
N/ARecruiting
201920202021202220232024202520262027202820292030
Enrollment StartFeb 2019
First PostedAug 2019
TodayJul 2026
Primary CompletionFeb 2030
Study CompletionAug 2030
First PostedAug 30, 2019
Enrollment StartFeb 1, 2019
Primary CompletionFeb 1, 2030
Study CompletionAug 1, 2030
TodayJul 2, 2026
Enrollment to primary: 11 yearsPosted 6.8 years agoPrimary completion in 3.6 years
Interventions
Radiation therapyradiation
Radiation therapy on the CE marked and FDA approved MR-Linac